Story perspectives

FDA Slams Pharma Giants for Misleading Weight-Loss Ads

9/16/2025

41 4

Summary

Story summary

The FDA warned Eli Lilly, Novo Nordisk, and Hims & Hers for misleading advertising of weight-loss drugs, part of a broader initiative against pharmaceutical marketing.
The letters, dated September 9, address claims about drugs like Zepbound, Mounjaro, Wegovy, and Ozempic, noting omitted safety risks.
Hims & Hers faced criticism for marketing compounded semaglutide, suggesting it is equivalent to FDA-approved drugs.
FDA Commissioner Marty Makary stressed the importance of balanced drug information in advertising.
Following the news, Hims shares dropped over 7%, while Lilly shares increased by 2.6%.

1 of 1

Story summary

The FDA warned Eli Lilly, Novo Nordisk, and Hims & Hers for misleading advertising of weight-loss drugs, part of a broader initiative against pharmaceutical marketing.
The letters, dated September 9, address claims about drugs like Zepbound, Mounjaro, Wegovy, and Ozempic, noting omitted safety risks.
Hims & Hers faced criticism for marketing compounded semaglutide, suggesting it is equivalent to FDA-approved drugs.
FDA Commissioner Marty Makary stressed the importance of balanced drug information in advertising.
Following the news, Hims shares dropped over 7%, while Lilly shares increased by 2.6%.